Drug Discovery for Parkinson's With Mutations in the GBA Gene
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNew York Stem Cell Foundation Research Institute
About this trial
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use.
Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.
Eligibility criteria
Qualifiers
Age 18 years or older.
Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
Must provide written informed consent unless physical limitations preclude signing.
Disqualifiers
For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.
Trial design
Treatments tested in this trial
- Biological Sample Collection
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
New York Stem Cell Foundation Research Institute
Lead sponsor
Silverstein Foundation
Collaborator
Source ClinicalTrials.gov